Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action

详细信息    查看全文

• 作者：William A Wells ; PhD^a ; Catharina C Boehme ; MD^b ; Prof Frank GJ Cobelens ; PhD^c ; Colleen Daniels ; MA^d ; David Dowdy ; MD^e ; Elizabeth Gardiner ; MSc^a ; Jan Gheuens ; PhD^f ; Peter Kim ; MD^g ; Michael E Kimerling ; MD^f ; Barry Kreiswirth ; PhD^h ; Christian Lienhardt ; PhDⁱ ; Khisi Mdluli ; PhD^a ; Madhukar Pai ; MD^j ; Mark D Perkins ; MD^b ; Trevor Peter ; PhD^k ; Matteo Zignol ; MDⁱ ; Prof Alimuddin Zumla ; FRCP^l ; ^m ; Dr Marco Schito ; PhDⁿ ; ^{schitom@niaid.nih.gov}
• 刊名：The Lancet Infectious Diseases
• 出版年：2013
• 出版时间：May, 2013
• 年：2013
• 卷：13
• 期：5
• 页码：449-458
• 全文大小：107 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

New tuberculosis drug regimens are creating new priorities for drug susceptibility testing (DST) and surveillance. To minimise turnaround time, rapid DST will need to be prioritised, but developers of these assays will need better data about the molecular mechanisms of resistance. Efforts are underway to link mutations with drug resistance and to develop strain collections to enable assessment of new diagnostic assays. In resource-limited settings, DST might not be appropriate for all patients with tuberculosis. Surveillance data and modelling will help country stakeholders to design appropriate DST algorithms and to decide whether to change drug regimens. Finally, development of practical DST assays is needed so that, in countries where surveillance and modelling show that DST is advisable, these assays can be used to guide clinical decisions for individual patients. If combined judiciously during both development and implementation, new tuberculosis regimens and new DST assays have enormous potential to improve patient outcomes and reduce the burden of disease.